Location: Foreign Animal Disease Research
Project Number: 3022-32000-063-043-S
Project Type: Non-Assistance Cooperative Agreement
Start Date: Jul 8, 2024
End Date: Jul 7, 2025
Objective:
Evaluate the ability for ASFV vaccine candidates ASFV-G-DeltaI177L and ASFV-G-DeltaI177L/dCD2 to be stable in terms of attenuation and genome by performing reversion to virulence studies in swine according to current WOAH guidelines.
Approach:
Recombinant ASFV-G-deltaI177L is a rationally developed ASFV live attenuated vaccine that has recently been approved for commercial production by the government of Vietnam. ASFV-G-dI177LdCD2 is a derivative of the ASFV-G-deltaI177L vaccine containing an deletion in CD2, a serological marker that can be used to determine if an animal is vaccinated or infected with ASFV. Both viruses were developed by genetic manipulation of the highly virulent ASFV Georgia 2010 (ASFV-G) isolate (genotype II). Recently draft guidelines have been established for reversion to virulence studies, a safety study for any live attenuated vaccine. In this study using controlled conditions and specific innoculums, both vaccines will be passed though swine 5 times. During this experiment, swine will be observed for clinical symptoms of ASFV.
